Community Health Systems, Inc. is one of the largest hospital operators in the United States. The company's affiliates develop and operate healthcare delivery systems across 32 distinct markets in 12 states. As of late October 2026, its subsidiaries owned or leased 59 affiliated hospitals with more than 8,000 beds, alongside more than 800 sites of care, including physician practices, urgent care centers, freestanding emergency departments, imaging centers, cancer centers, and ambulatory surgery centers.
The company generates revenue primarily from general acute care, emergency, surgical, and outpatient services. Investors follow CYH for its exposure to hospital volumes, payor mix trends, reimbursement rates, and its ongoing strategy of divesting lower-performing hospitals while expanding higher-return outpatient assets and ambulatory surgery centers.
Over the trailing 30 days, CYH declined approximately 45.9%, moving from a closing price of $2.82 on October 21, 2026, to roughly $1.53 on November 20, 2026. The sharpest leg of the decline occurred in late October, when the stock fell about 9.4% in a single session after third-quarter results, and the downward pressure continued through November. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The quarterly picture is similarly weak. From a closing price near $2.98 in mid-August 2026, the stock has fallen roughly 48% into the low-$1.50 range. The trend was punctuated by a brief rally into early-to-mid October, when CYH traded above $3.00, before selling pressure returned and erased those gains.
The dominant catalyst was the company's third-quarter 2026 earnings report, released after the market close on October 28, 2026. CYH reported net operating revenues of $2.757 billion, down 10.7% from $3.087 billion a year earlier, and a net loss attributable to stockholders of $86 million, or $0.63 per diluted share, versus net income of $130 million, or $0.96 per diluted share, in the same period of 2025. Adjusted EBITDA fell to $280 million from $376 million a year earlier.
Adjusted earnings per share came in at a loss of $0.48, below analyst estimates, and the company missed revenue expectations. Management also lowered its full-year 2026 guidance, projecting net operating revenues of $11.3 billion to $11.5 billion, adjusted EBITDA of $1.225 billion to $1.275 billion, and a wider diluted net loss per share. The company pointed to rising uninsured volumes, softness in commercial elective procedures, higher medical specialist fees, and an unfavorable payor mix. Net leverage rose to 7.2x from 6.6x at year-end 2025, despite $810 million in debt reduction year-to-date.
Analyst actions added to the pressure. Following the report, at least one firm maintained an underweight rating and lowered its price target, while another cut its target as well.
The broader multi-month decline reflects a combination of weakening profitability, an unfavorable mix shift, and continued portfolio restructuring. Same-store net revenue grew 3.8% in the third quarter, with admissions and adjusted admissions up 2.2% and 3.6%, respectively, but nearly half of adjusted-admission growth came from uninsured patients. Higher-acuity, higher-reimbursement commercial elective procedures remained below expectations, while medical specialist costs rose 13% year-over-year, driven by anesthesia and radiology.
The company has also continued divesting hospitals, completing a series of divestitures during 2026. While these sales reduce reported revenue and reduce debt, they also shrink the earnings base. Investors weighed these structural headwinds against management's cost-cutting efforts, outpatient expansion, and technology investments, ultimately driving a sustained repricing of the stock lower over the quarter.
Looking ahead, investors are likely to monitor several factors. First, the company's next quarterly report and any updates to full-year guidance will be closely watched, particularly around adjusted EBITDA trends and cash flow from operations. Second, payor mix dynamics, including the level of uninsured volumes and any recovery in commercial elective procedures, will be key to margin recovery. Third, medical specialist fee inflation in anesthesia and radiology remains a cost pressure to track.
Other areas of focus include the pace and financial impact of ongoing hospital divestitures, net leverage trends, reimbursement and regulatory developments such as state-directed payment programs, and progress on outpatient and ambulatory expansion. Macroeconomic conditions affecting patient ability to pay copays and deductibles may also influence demand. These factors present both risks and potential catalysts, and investors should monitor them closely rather than relying on any single projection.
In my analysis of names like this, I often turn to Tickeron's AI Trading Bots to review rules-based strategies across different market environments. These tools provide a practical way to compare automated approaches and identify patterns that align with my own research process, helping me stay disciplined without replacing judgment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
The Aroon Indicator for CYH entered a downward trend on November 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 230 similar instances where the Aroon Indicator formed such a pattern. In 202 of the 230 cases the stock moved lower. This puts the odds of a downward move at 88%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYH as a result. In 68 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for CYH turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 42 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
CYH moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CYH crossed bearishly below the 50-day moving average on October 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYH advanced for three days, in 221 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CYH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.224) is normal, around the industry mean (204.532). P/E Ratio (1.176) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.498). Dividend Yield (0.452) settles around the average of (0.153) among similar stocks. P/S Ratio (0.034) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. CYH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an operator of general acute care hospitals
Industry HospitalNursingManagement